Basic Information
| LncRNA/CircRNA Name | AC093850.2 |
| Synonyms | NA |
| Region | GRCh38_2:215718043-215719424 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | esophageal squamous cell carcinoma |
| ICD-0-3 | NA |
| Methods | RNA-seq, Microarray, qPCR, in vitro knockdown |
| Sample | ESCC tissues, Human esophageal cancer cell lines (KYSE150,KYSE180, KYSE450, KYSE70, KYSE140 and TE3) |
| Expression Pattern | up-regulated |
| Function Description | A novel three-lncRNA signature, comprised of RP11-366H4.1.1 (ENSG00000248370), LINC00460 (ENSG00000233532) and AC093850.2 (ENSG00000230838), was identified. The signature classified patients into high-risk and low-risk groups with different overall survival (OS) and disease-free survival (DFS). The signature indicates that patients in the high-risk group show poor OS and DFS, whereas patients with a low-risk group show significantly better outcome. The independence of the signature was validated by multivariable Cox regression analysis. GO and KEGG pathway analysis for 588 protein-coding genes-associated with the three lncRNAs indicated that the three lncRNAs were involved in tumorigenesis. In vitro assays further demonstrated that the three lncRNAs promoted the migration and proliferation of ESCC cells. |
| Pubmed ID | 29409459 |
| Year | 2018 |
| Title | A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma. |
External Links
| Links for AC093850.2 | GenBank HGNC NONCODE |
| Links for esophageal squamous cell carcinoma | OMIM COSMIC |